Category Archives: Public Policy

Latest From Public Policy

Global Biotechnology IP Evaluation by Scientific American

Scientific American evaluated the strength of intellectual property in 48 countries (click on chart on top left side of story for data) in its Worldview Scorecard including a chart with country rankings. This data* is based on patentable inventions, membership of international treaties, duration of protection, enforcement mechanisms and restrictions (e.g., compulsory licensing). The U.S. holds the top spot, followed closely by Belgium, Canada, Denmark, Finland, France, Ireland, Italy, Japan, and the Netherlands (all tied Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

Scientific American on BRIC’s IP Environment

Scientific American World View issued a special report at this year’s 2011 BIO International Convention that had several references to IP protections around the world but focused particularly on the BRIC countries (Brazil, Russia, India, and China).  See below for interesting takes on the IP environment in each country. China: Patently Ambiguous asserts that while “China’s intellectual property environment remains challenging at best” several involved on the ground in China believe that “there should be Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,

Taiwan’s Translational Research (or lack thereof)

Taiwan Flag - Matthew Fang

Brady Huggett concludes in this article that, “… perhaps the biggest strike against Taiwan is a lack of translational research. There is no collective mindset that envisions products from research. And if biotech is to drive the future economies of countries around the globe, there has to be nationwide efforts to turn academic research and publicly-funded lab work into something that can benefit patients and be sold. We’ve talked about it before on this blog Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Myriad Genetics’ actions justify a ban on gene patents?

Virus

The following information was provided by Myriad’s General Counsel during his presentation on the subject during a recent BIO IP conference: In order to develop and then ensure the widest possible distribution of the Myriad BRCA diagnostic test, Myriad needed to make the initial discovery, educate the medical community on the values of personalized medicine (the BRCA test), convince insurance companies to cover the test, and educate the patient community.  All of these activities took Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Banning Gene Patents Will Promote Innovation?

Hampton Roads Partnership

Abolishing gene patents will deter, not promote, innovation, as the patent eligibility of isolated DNA molecules provides incentives necessary for development of life-enhancing diagnostics and therapeutics. R&D to identify genes, their sequences, genetic variations, and their disease  correlation is very costly. Claims like those of the patents at issue in the Myriad Genetics lawsuit have been a key foundation supporting the massive investment of time and capital that is necessary to bring life-enhancing DNA-based diagnostics Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,